HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained a price target of $9.
August 14, 2024 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Aquestive Therapeutics and maintained a price target of $9.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100